Resilience: Advancing Medicines That Matter - CDMO Capabilities Overview

Moving a biologic from development to finished goods usually means coordinating several sites, handoffs, and regulatory touchpoints.

This overview shows how one North American CDMO network structures that path across facilities in Blue Ash, West Chester, and Toronto. It covers single-use bioreactor capacity from 50L to 2,000L, aseptic filling of vials, prefilled syringes, and cartridges, plus device assembly, serialization, and cold-chain logistics. It also outlines the inspection record behind the operation, including a 100% pass rate for third-party and EU Annex 1 assessments. Programs can enter at development, drug substance, drug product, or with material already made.

Explore the capabilities to see where a program could fit.